Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina

Executive Summary

Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.

Advertisement

Related Content

Novo Nordisk Grabs Shark Antibody-Based CNS Delivery Technology From Ossianix
Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge
Finance Watch: Ascletis First Biotech To List Under New Hong Kong Rules, BeiGene Joins In
Aquinox, Astellas Mull Options As Rosiptor Fails
Can Takeda Help Deliver Shire's China Rare Disease Dream?
Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
Almirall To Put More Skin In The Game With Derma Buys
Takeda To Unlock More Cash As It Preps For Shire
After APOLLO: Trevena Weighs Commercial Viability Of Opioid Oliceridine
Medigene's bluebird Deal Validates TCR Technology And Immune-Oncology Strategy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel